Cormorant leads $50M private placement in Cue Biopharma
What's the deal? Cue BiopharmaDealroom has a profile for this one. Try Dealroom →, a Nasdaq-listed clinical-stage biopharmaceutical company, has raised roughly $50 million through a private placement led by Cormorant Asset Management. Columbia Threadneedle InvestmentsDealroom has a profile for this one. Try Dealroom → and other new investment funds also joined the round, which is expected to close on or about July 13, 2026.
The details: The deal covers 1,418,071 shares of common stock plus pre-funded warrants for up to 87,500 shares. Cue plans to use the proceeds to fund clinical development and for general corporate purposes.
What's the endgame? Boston-based Cue is developing therapies aimed at functional cures for immunological disorders. Its lead asset is an anti-IgE antibody in Phase 2 for allergic diseases, while autoimmune candidate CUE-401 is advancing towards Phase 1.
Why now? The company expects near-term clinical milestones, including data from Ascendant Health's ongoing Phase 2 study of chronic spontaneous urticaria in China by the end of the third quarter of 2026.
What they said: Chief executive officer Shao-Lee LinDealroom has a profile for this one. Try Dealroom → pointed to a "high-quality group of biotech investors committing to the long-term support of Cue as we build our company."
The signal: The backing of Cormorant — a specialist biotech investor — signals conviction in Cue's pipeline ahead of key trial readouts, a notable vote of confidence for a clinical-stage company still years from market.
Read more: MarketScreener
Image credit: Generated with Gemini
